Arch Venture Management’s Maze Therapeutics MAZE Stock Holding History

Arch Venture Management’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123M	Hold	4,120,053	–	–	11.18%	7
2026 Q1	$123M	Hold	4,120,053	–	–	18.16%	1
2025 Q4	$171M	Hold	4,120,053	–	–	26.19%	1
2025 Q3	$107M	Hold	4,120,053	–	–	21.7%	3
2025 Q2	$50.6M	Hold	4,120,053	–	–	16.91%	3
2025 Q1	$45.4M	Buy	+4,120,053	New	+$49.6M	22%	2

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Arch Venture Management's MAZE Position: Q2 2026 in Review

Arch Venture Management held its Maze Therapeutics (MAZE) position steady in Q2 2026 at 4,120,053 shares worth $123M. The position accounts for 11.18% of the portfolio, ranked #7.

Arch Venture Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $171M in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Arch Venture Management held 4,120,053 shares of Maze Therapeutics worth $123M as of Q2 2026.
Arch Venture Management left its Maze Therapeutics share count unchanged in Q2 2026.
Maze Therapeutics made up 11.18% of Arch Venture Management's portfolio in Q2 2026, its #7 holding.
Arch Venture Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
Arch Venture Management's Maze Therapeutics position peaked at $171M in Q4 2025.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.